Parkinson’s disease is the fastest growing neurological disorder in the world. Over the past 25 years, the number of people with the condition has jumped from 3 million to over 6 million. By 2040, the number will likely double again. We are failing to stop this onslaught. […] At the same time, our investment in new therapies has lagged behind the disease and many people remain undiagnosed and untreated.
(Dorsey, Sherer, Okun, Bloem. Ending Parkinson’s Disease, 2020)
Misfolded protein aggregates have been found to be a common hallmark of several neurodegenerative disorders known as proteinopathies. Aggregates not only result in a loss of function of the protein but often overwhelm the clearance system of the cell and become toxic. Parkinson’s and Alzheimer’s diseases are among the most prevalent neurodegenerative proteinopathies.
DISCOVERY
It’s difficult to
source potential new treatments
It’s difficult to
get treatments past the blood brain barrier
DEVELOPMENT
It’s difficult to
predict potential adverse effects
It’s difficult to
know which patients will respond to treatment
1- Beach et al., Acta Neuropathol, 2010
2- Scherperjans et al., Movement Disorders, 2015
3- Boertien et al., J Parkinsons Dis, 2019
4- Vogt et al., Sci Rep, 2017
5- Zhuang et al., J Alzheimers Dis, 2018
6- Sampson et al., Cell, 2016
7- Kim et al., Gut, 2020
© 2022 Stellate Therapeutics. All Rights Reserved.
France HQ – 47 Rue de Montmorency, 75003 Paris Stellate Inc. – 101 Avenue of the Americas, JLABS @ NYC, New York, NY 10013
© 2022 Stellate Therapeutics. All Rights Reserved.